Table 3.

Potential regimens of LAMB that have been developed for use against VL^*.

Regimen	Cost (USD) [70]	Efficacy (phase of trial done)	Comments
LAMB i.v. 10 mg/kg single dose	126	95% (P3)	South Asia only, poor efficacy in East Africa
LAMB 20 mg/kg over 4 doses	252	98% (P4)	South Asia only and possibly Europe and Latin America, poor efficacy in East Africa
LAMB 5 mg/kg + MF 100 mg/kg/day for 8 days	88 – 109	97.5% (P3)	South Asia only; teratogenicity of MF may hinder uptake
LAMB 5 mg/kg + PM 15 mg/kg/day for 11 days	79	97.5% (P3)	South Asia only; use of daily PM injections may hinder uptake
LAMB 30 mg/kg over 6 – 10 doses	378	90% (observational field data only)	East Africa only; no clinical trial data available at this dose

*Based on data from the WHO expert committee report 2010.

LAMB: Liposomal amphotericin B (all trials here have used AmBisome^™); MF: Miltefosine; PM: Paromomycin.